Journal Logo

SUPERIORITY OF CYBORD OVER VAD IS MORE EVIDENT IN FIRST THAN IN SECOND LINE TREATMENT OF MULTIPLE MYELOMA

PB2183

El Gammal, M.1; Hassan, N.2; Fatah, Abdel M.3

doi: 10.1097/01.HS9.0000567212.75019.39
Publication Only: Myeloma and other monoclonal gammopathies - Clinical
Free

1Medical Oncology

2Clinical and chemical pathology department, NCI, Cairo University, Cairo

3Clinical Oncology dep, El Fayoum faculty of medicine, Egypt, El Fayoum, Egypt

Back to Top | Article Outline

Background:

In the era of novel anti-myeloma agents and monoclonal antibodies (daratumumab) and due to their high cost, earlier low cost regimens (VAD or CyBorD) may be used.

Back to Top | Article Outline

Aims:

to compare outcome of treatment of CyBorD versus VAD regimens in multiple myeloma

Back to Top | Article Outline

Methods

This cohort study included 89 MM patients treated at National Cancer Institute (NCI), Cairo, Egypt from January 2011 to December 2015. All patients were evaluated clinically and laboratory for different responses with either lines of treatment (VAD versus CyBorD), and correlated with different survival parameters; progression free (PFS), disease free (DFS), and overall survival (OS), and clinico-pathologic factors.

Back to Top | Article Outline

Results:

The median age of patients was 54 years (32-76), with male predominance (male to female ratio 1.87:1). The most common presenting symptoms were bony pains (44.9%) followed by bony masses (22.5%), fractures (16.9%), pallor (7.9%), neurological symptoms (5.6%) and finally oliguria (2.2%). CyBorD have better overall response rate (≥PR) (p = 0.031), PFS (p = 0.004) and DFS (p= 0.013) as 1st line treatment compared to VAD regimen. Also in previously treated patients CyBorD showed better PFS (p = 0.039) compared to VAD regimen. There was a significant relation between age (p = 0.001& < 0.001) and ASCT (p= 0.001&0.034) with PFS and OS respectively.

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

CyBorD have significant better overall response treatment (≥PR), PFS and DFS in 1st line treatment compared to VAD regimen. While in previously treated patients only PFS benefit for CyBorD over VAD regimen was obtained. Age and ASCT had significant effect on PFS and OS

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.